Bristol-Myers Squibb CompanyBMYNYSE

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

30 analysts·High coverage

43%

Rating Distribution

Strong Buy

00%

Buy

1343%

Hold

1550%

Sell

27%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 3% above analyst consensus — near fair value expected.

Bear Case

$40.00

-35%

Consensus

$60.11

-3%

Bull Case

$72.00

+16%

Price Range30 analysts

Low

Consensus

High

$40.00

$72.00

Current Target

Current Price

$61.99

Above Target

$1.88

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$6.13(11 analysts)

P/E18x

Current: 17.9x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-2.65%

EPS-2.68%

FY2028

Rev-9.86%

EPS-9.81%

FY2029

Rev-8.28%

EPS-9.42%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+12.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 6, 2026Morgan Stanley

Bristol Myers price target raised to $40 from $37 at Morgan Stanley

Target:$40.00

-35.3%from $61.86

Feb 6, 2026Guggenheim

Bristol Myers price target raised to $72 from $62 at Guggenheim

Target:$72.00

+21.0%from $59.52

Feb 6, 2026Wells Fargo

Bristol Myers price target raised to $60 from $55 at Wells Fargo

Target:$60.00

+0.8%from $59.52

Jan 28, 2026Piper Sandler

Bristol Myers price target raised to $66 from $62 at Piper Sandler

Target:$66.00

+18.8%from $55.56

Jan 13, 2026Leerink Partners

Bristol Myers price target raised to $60 from $54 at Leerink

Target:$60.00

+6.4%from $56.39

Jan 9, 2026Scotiabank

Bristol Myers price target raised to $60 from $53 at Scotiabank

Target:$60.00

+7.4%from $55.87

Jan 7, 2026UBS

Bristol Myers upgraded to Buy from Neutral at UBS

Target:$65.00

+15.2%from $56.41

Dec 12, 2025Morgan Stanley

Bristol Myers price target raised to $37 from $36 at Morgan Stanley

Target:$37.00

-29.7%from $52.63

Dec 12, 2025Guggenheim

Bristol Myers upgraded to Buy from Neutral at Guggenheim

Target:$62.00

+21.1%from $51.20

Dec 10, 2025HSBC

Bristol Myers price target raised to $53 from $50 at HSBC

Target:$53.00

+4.6%from $50.68

Dec 4, 2025Scotiabank

Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Scotiabank

Target:$53.00

+4.0%from $50.96

Dec 3, 2025Truist Financial

Truist Securities on Bristol-Myers Squibb Co. (BMY): 'overall positive'

Target:$65.00

+27.5%from $50.98

Aug 5, 2025Daiwa

Bristol Myers downgraded to Neutral from Outperform at Daiwa

Target:$42.00

-8.4%from $45.85

Jul 21, 2025Truist Financial

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Target:$84.00

+78.3%from $47.12

Apr 23, 2025Jefferies

Bristol Myers price target lowered to $68 from $70 at Jefferies

Target:$68.00

+40.1%from $48.52

Apr 22, 2025Piper Sandler

Piper Sandler bullish on Bristol Myers, initiates with an Overweight

Target:$65.00

+30.5%from $49.82

Nov 12, 2024BMO Capital

Bristol Myers price target raised to $61 from $57 at BMO Capital

Target:$61.00

+8.5%from $56.23

Nov 1, 2024BMO Capital

Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital

Target:$57.00

+4.9%from $54.32

Sep 23, 2024BMO Capital

BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

Target:$48.00

-3.1%from $49.56

Jul 29, 2024Goldman Sachs

Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs

Target:$57.00

+12.8%from $50.55

Jul 29, 2024Barclays

Bristol Myers downgraded to Underweight from Equal Weight at Barclays

Target:$41.00

-18.7%from $50.45

Jul 12, 2024UBS

Bristol Myers price target lowered to $43 from $47 at UBS

Target:$43.00

+5.7%from $40.68

May 16, 2024Cowen & Co.

TD Cowen Reiterates Hold Rating on Bristol-Myers Squibb Co. (BMY)

Target:$67.00

+51.9%from $44.11

Jan 30, 2024Deutsche Bank

Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?

Target:$55.00

+10.3%from $49.87

Nov 27, 2023BMO Capital

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

Target:$60.00

+20.6%from $49.76

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance